# 1 Early Experience with Ivabradine for Focal Atrial Tachycardia in

2	Pediatric Patients with Congenital Heart Disease		
3	Drishti Tolani <sup>1</sup> MBBS, Nawin L. Ramdat Misier <sup>1,2</sup> BSc, Manal Alqahtani <sup>1</sup> MBBS, Kaitlin Tindel <sup>3</sup>		
4	PharmD, William A. Scott <sup>1</sup> MD, Hoang H. Nguyen <sup>1,2</sup> MD		
5			
6	<sup>1</sup> Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA		
7	<sup>2</sup> Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands		
8	<sup>3</sup> Department of Pharmacy, Dallas Children's Medical Center, Dallas, Texas, USA		
9			
10			
11	Short title: Ivabradine for AT in CHD pediatrics		
12	Word count: 3201		
13	Disclosures: None		
14			
15	Correspondence to:		
16	Hoang H. Nguyen MD		
17	The University of Texas Medical Center		
18	5323 Harry Hines Boulevard		
19	Dallas, TX 75235		
20	E-mail: <u>hoang.nguyen@utsouthwestern.edu</u>		

#### 21 Abstract

Background: Ivabradine is a promising anti-arrhythmic therapy for automatic arrhythmias such as inappropriate sinus tachycardia, junctional ectopic tachycardia, and focal atrial tachycardia (AT). However, experience with ivabradine in pediatric patients, especially those with congenital heart disease (CHD) and focal AT, remains limited. We report our findings using ivabradine for focal AT in infants and children with CHD to assess its efficacy and safety.

28 Method: A retrospective analysis was conducted on all pediatric patients (<21 years) 29 diagnosed with CHD at Children's Health of Dallas, who were treated with ivabradine for 30 focal AT. Patient demographics, arrhythmia diagnosis, anti-arrhythmic therapies, and 31 adverse effects were evaluated. A positive response was defined as complete rhythm control 32 within 24 hours of initiation of ivabradine.

Results: Fifteen patients (median age 7 [1-8] months; 9 males (60%)) were included in this study, including 12 (80%) complex CHD. Fourteen patients (93%) had unifocal AT and one (7%) had multifocal AT. The AT occurred in the early post-operative period in six patients (40%). In two patients (13%) ivabradine was used as monotherapy. Positive response to ivabradine was observed in 12 patients (80%). Adverse events occurred in 7 patients (47%) consisting of bradycardic, which was transient, or resolved upon reducing the ivabradine dosage.

Conclusion: In infants and children with CHD, ivabradine was efficacious for the treatment of
focal AT without major complications. Bradycardia is a frequent adverse event. Therefore,
close monitoring may be required during initiation of therapy.

43 Key words: pediatric, atrial tachycardia, congenital heart disease, anti-arrhythmic agent

## 44 Abbreviations

- 45 AT= atrial tachycardia
- 46 CHD= congenital heart disease
- 47 JET= junctional ectopic tachycardia

#### 48 Introduction

49	Ivabradine is an anti-arrhythmic agent that reduces the heart rate by inhibiting the
50	pacemaker current, which is responsible for spontaneous depolarization of the sinoatrial
51	node.(1) Currently, ivabradine is primarily used for treatment of inappropriate sinus
52	tachycardia and sinus tachycardia related to heart failure, in adults.(2, 3) More recently,
53	there has been increasing experience with ivabradine for junctional ectopic tachycardia (JET)
54	in pediatric patients.(4) As abnormal spontaneous diastolic depolarization is the
55	pathophysiologic mechanism for focal atrial tachycardia (AT), i ivabradine may be an
56	effective therapy.(5)
57	Experience with ivabradine in pediatric patients with focal AT is limited to small case series,
58	often lacking patients with congenital heart disease (CHD).(6-11) In young patients with CHD,
59	AT is a significant source of morbidity and mortality.(12, 13) Multiple anti-arrhythmia agents
<u> </u>	

are moderately effective in treating AT; however, all have potentially significant side effects, 60 61 which could outweigh their benefits.(12-14) An important advantage of ivabradine is its high

62 selectivity. It does not have negative inotropic effects or prolong repolarization.(1, 4, 15)

63 We, therefore, report in this single-center study our early experience using ivabradine for 64 focal AT in infants and children with CHD to assess its efficacy and safety.

#### 65 Methods

A retrospective review was conducted on all pediatric patients at Children's Health of Dallas who were treated with ivabradine for focal AT. The inclusion criteria for the study were pediatric patients <18 years with CHD and focal AT, who were treated with ivabradine as inpatients.

Our center has been using ivabradine for AT since August 2020, and all retrospective data available from August 2020 until May 2023 were collected. Local institutional review board approval was obtained, and informed consent was waived.

#### 73 Ivabradine protocol

Data were retrieved from medical records and included demographic characteristics, type of
 CHD, date and types of cardiac procedures, comorbidities, pharmacological therapy before
 ivabradine treatment, electrocardiographic recordings, and echocardiographic recordings.

Analysis of inpatient telemetry, standard 12 lead electrocardiogram and atrial wire studies
were utilized for diagnosis. Focal AT was confirmed by a pediatric electrophysiologist.
Incessant focal AT was defined as a continuous tachycardia without spontaneous
termination or continuous paroxysms of tachycardia separated by ≤2 sinus beats and lasting
>24 hours.

Pediatric patients were treated with ivabradine when able to receive PO medication. Decision to initiate ivabradine was left to the treating electrophysiologist in consultation with the primary care team. In general, first-line treatment with ivabradine was considered when the AT was not critical. Ivabradine was also used as second or third-line agent to supplement or replace medications that were not completely effective. Generally,

medRxiv preprint doi: https://doi.org/10.1101/2023.06.07.23291097; this version posted June 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

87 ivabradine was administered at an initial dose of 0.05 mg/kg (a dosage of 2.5 mg for patients 88 weighing<sup>2</sup>><sup>2</sup>30 kg) every 12 hours under continuous telemetry of ECG and oxygen 89 saturation. Blood pressure was monitored by indwelling line or frequent noninvasive 90 measurements. Treatment was considered successful if rhythm control was achieved within 91 24 hours of ivabradine initiation. The dosage of ivabradine was increased to 0.1 mg/kg, when 92 the first dose showed no effect on the heart rhythm or rate. If ivabradine was not successful 93 within 24 hours, it was discontinued. In patients for whom first-line ivabradine was 94 ineffective, other antiarrhythmic drugs were prescribed. In cases of successful ivabradine 95 therapy, ongoing discussion with the primary care time determined the duration of therapy. 96 Ivabradine dosage was lowered for clinically relevant bradycardia. Side effects, including 97 acute hemodynamic changes, bradycardia and pro-arrhythmia, were specifically sought out.

#### 98 Statistical analysis

99 Continuous data were described as medians [ranges] and categorical variables were 100 described as counts and percentages. Estimated statistics were performed for statistical 101 comparison.(16)

#### 102 **Results**

#### 103 Study population

104 Fifteen patients (9 males (60%)) were included in this study. The median age at ivabradine

initiation was 7 [1-8] months, with 6 patients (40%) being younger than 3 months old. Of the

- 106 12 the patients with complex CHD, 8 patients had single ventricle physiology and six patients
- 107 had heterotaxy syndrome. Four patients (27%) had diminished systolic ventricular function.
- 108 Baseline characteristics of the study are summarized in **Table 1**.

Fourteen patients (93%) had unifocal ectopy AT and one patient (7%) had multifocal AT. In total, six patients (40%) developed AT early after cardiac surgery or interventional catheterization. Six out of 15 ATs were incessant. None of the patients had prior atrial or ventricular arrhythmias.

#### 113 Ivabradine regimen

114 Ivabradine was used as first-line therapy in 4 patients (27%), second-line therapy in 6 (40%) 115 and third line in 1 (7%) (Table 1). In 4 additional patients (27%), ivabradine was administrated to avoid breakthrough of ATs. In total, 13 patients (87%) used ivabradine in 116 117 combination with other anti-arrhythmic medications, while only a minority (13%) used it as 118 monotherapy. Ten patients (67%) were on a combination of ivabradine and one other antiarrhythmic agent, including beta-blocker (N=2), flecainide (N=2), dexmedetomidine (N=2), 119 120 amiodarone (N=2) and digoxin (N=2). Three patients (20%) were on a combination with  $\geq 2$ 121 anti-arrhythmic drugs: ivabradine with flecainide and amiodarone; ivabradine with a beta-122 blocker and amiodarone; or ivabradine with a beta-blocker, flecainide, and digoxin.

The initial ivabradine dosage was 0.05 [0.05-0.05; min 0.02 – max 0.1) mg/kg. Two patients received adult dosing at 2.5 mg (34 kg) and 5 mg (70 kg), resulting in 0.07 mg/kg in both respectively. The maximum dosage during treatment was 0.07 [0.05-0.1; min 0.038-max 0.157) mg/kg, which was higher than the initial dose in 7 patients (all <1 year of age).

127 *Efficacy outcomes* 

Positive response to ivabradine was observed in 12 patients (80%). During their in-hospital 128 129 stay, they were treated with ivabradine for a median duration of 6 [5-26] days, and none had 130 recurrence while on ivabradine therapy. In 3 patients (20%), all with post-operative AT, 131 ivabradine was unsuccessful in providing adequate rhythm control. The first patient had 132 incessant AT which did not respond to ivabradine despite optimization of the dose. After 133 discontinuation of ivabradine, rhythm control was achieved with after initiation of multiple 134 other anti-arrhythmic agents. The second patient continued to have multifocal AT on 135 ivabradine, although a more organized rhythm was observed. The third patient remained to 136 have breakthrough focal AT on ivabradine. After addition of flecainide, the patient was free 137 of AT.

After discharge, 3 of the 12 responders (25%) no longer required treatment. Two patients (13%) had mono-drug therapy with ivabradine after discharge. The first patient was initially weaned off ivabradine after discharge, but had recurrent AT 1 year after discharge, which responded to ivabradine. The second patient received maintenance therapy with ivabradine, without recurrence during follow-up. The 7 other patients (58%) either continued using one or multiple other antiarrhythmic drugs, without ivabradine.

144 Safety outcomes

In total, 7 patients experienced adverse events (47%), all consisting of bradycardia alone.
Bradycardia occurred at a median of 3 [IQR 1-3] days after initiation of ivabradine, with a
maximum of 7 days. Five patients had sinus bradycardia, and 2 had functional bradycardia
due to blocked premature atrial contractions (PACs). All patients with bradycardia were
receiving concomitant anti-arrhythmic agents. Using estimated statistics, the unpaired
median differences in age between patients with and without bradycardia was -3.5 [95.0%Cl
-85.0, 7.5] months (two-sided permutation t-test P value = 0.492).

152 In 4 patients, either a single dose was skipped or the chronic dose was halved, which successfully restored sinus rhythm within 12 hours. In 1 patient, ivabradine was discontinued 153 154 due to bradycardia after conversion to sinus rhythm, after which patient had recurrence of AT. Flecainide and propranolol successfully terminated the AT, but the AT recurred once 155 these medications were discontinued. Subsequently, ivabradine was initiated again and 156 157 successfully converted the AT to sinus rhythm without AT or bradycardia recurrence. In 158 another patient ivabradine was replaced by flecainide which resolved the functional bradycardia. In the remaining 2 patients ivabradine regimen was not changed during well 159 160 tolerated bradycardia that spontaneously resolved later the same day.

#### 161 **Discussion**

#### 162 Key findings

163 In this retrospective single center study, we assessed for the first time the efficacy and safety 164 of ivabradine for focal AT in infants and children with CHD. The 80% response rate was high, 165 although often in combination with other anti-arrhythmic agents. Adverse events were 166 limited to bradycardia without significant clinical consequences.

#### 167 *Clinical experience with ivabradine*

168 In recent years, additional indications for ivabradine have been explored, particularly in 169 pediatric patients, due to the favorable side effect profile. (4, 6, 15) In these young patients, 170 Ivabradine has recently been shown to be a promising pharmacological agent in the treatment of heart failure and JET.(15) Similar to the adult population, there has also been 171 172 increasing interest in its use for automatic AT. However, the experience was limited to 173 several case-reports and small series in pediatrics, often with normal cardiac anatomy.(6-10) 174 Recently, Xu et all reported its single center experience with ivabradine monotherapy in 12 175 pediatric patients with focal AT and no CHD, who were resistant to conventional antiarrhythmic agents.(6) Ivabradine was effective in 50% of the patients, and well tolerated 176 without any events of bradycardia. However, except for a case-report, outcomes of 177 178 ivabradine in pediatric with congenital heart disease were unknown.(9)

Focal AT are not uncommon in pediatric patients with congenital heart disease, especially in the early post-operative period.(14) In these patients, AT is often associated with hemodynamic comprise and a three times higher mortality rate.(13) Not only are the current anti-arrhythmogenic agents characterized by suboptimal efficacy, they also have negative inotropic effects, potential for toxicity, and carry increased risks for other arrhythmias.(12-

14) In this vulnerable population, catheter ablation is often unattractive due to technical complexity, moderate success rates and risk for complications.(12, 14) We now demonstrate in a sizable population, that ivabradine is effective for treatment of focal AT in pediatric patients with CHD, often when other anti-arrhythmic agents failed. Moreover, its efficacy may be higher compared to pediatric patients (6/12, 50%) and adult patients with normal anatomy (18/34, 64%).(5, 6)

#### 190 Alternative mechanisms underlying focal AT

191 Although focal AT are from a mechanistic point of view due enhanced automaticity, it is not 192 restricted to this mechanism.(17) Micro-reentry and triggered activity may also underly focal 193 AT, which could explain the non-response in selected patients with focal AT. Various reports 194 show that these alternative mechanisms are frequent in pediatric and adult patients with 195 and without congenital heart disease. (17-19) In addition, increased automaticity – and thus 196 pacemaker activity – are not solely dependent on HCN channels, which are the electrical 197 target for ivabradine treatment. Enhanced function of other ionic channels and their 198 currents may also be responsible for spontaneous diastolic depolarizations in selected 199 patients with automatic FAT, rendering them insensitive to ivabradine.(1)

#### 200 Bradycardia and side effects

The minimal side-effect profile of ivabradine has been a major reason for the increased interest in ivabradine as an alternative anti-arrhythmic agent for focal AT.(1, 4, 6, 15) Unlike traditional anti-arrhythmic agents, ivabradine has minimal effects on blood pressure and inotropy. However, an important adverse effect is bradycardia.(15, 20) While there were no documented episodes of bradycardia in the case-series from Xu et al., we observed bradycardia in 47% of patients.(6) Interestingly, bradycardia was not just due to depressed

sinoatrial node pacemaker function, 2 out of 7 patients had functional bradycardia due to
blocked PACs. Ivabradine can also inhibit the funny current in the atrioventricular node,
resulting in functional bradycardia in presence of PACs.(21)

210 In pediatric patients with complex CHD, bradycardic events may be more significant as this 211 population often has diminished ventricular function. In addition, pediatric patients < 1 year 212 of age are especially dependent on chronotropic competence. Importantly, however, 213 bradycardic events in the current study were transient or responded to reducing the 214 ivabradine dosage. A recent report showed that in the case of ivabradine overdoses (0.5 215 mg/kg due to dosing error), bradycardia did not result in hemodynamic instability in a child 216 with AT. In addition, within 28 hours of discontinuation of ivabradine sinus rhythm was 217 returned.(11) Also, pediatric patients with early post-operative AT often have temporary 218 atrial or ventricular pacing wires which could ensure sufficient ventricular rate in case of 219 persisting bradycardia.

#### 220 Limitations

221 Although this is the first large retrospective single center report on the use of ivabradine in 222 pediatric with CHD, there are several limitations inherent to its design. Due to its 223 retrospective nature, there was no standardized protocol in initiation of ivabradine, resulting 224 in first, second and third-line therapy regimens in combination with various other antiarrhythmic agents. Future studies need to assess the efficacy and safety of monotherapy 225 226 separately from interaction with specific other anti-arrhythmic agents. Due to the relatively 227 small sample size, the study was unable to identify predictors for response, adverse events 228 and determine the optimal dose for treatment.

#### 229 Conclusion

- 230 In infants and children with CHD, ivabradine showed a high efficacy for the treatment of
- 231 focal AT without any major complications. Bradycardia is a frequent adverse event; although
- transient and short-lived, these events may require close monitoring especially in the post-
- 233 operative course.

## 234 Funding

- 235 Nawin Ramdat Misier is supported by a training grant from the Royal Netherlands Academy
- 236 of Arts and Sciences (KNAW)

## 237 References

Marciszek M, Paterek A, Oknińska M, Zambrowska Z, Mackiewicz U, Mączewski M.
 Effect of ivabradine on cardiac arrhythmias: Antiarrhythmic or proarrhythmic? Heart
 Rhythm. 2021;18(7):1230-8.

Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, et al.
 Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective,
 randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol.
 2012;60(15):1323-9.

245 3. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol succinate
246 vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive
247 to previous pharmacological therapy. Europace. 2013;15(1):116-21.

Arvind B, Kothari SS, Juneja R, Saxena A, Ramakrishnan S, Gupta SK, et al. Ivabradine
 Versus Amiodarone in the Management of Postoperative Junctional Ectopic Tachycardia: A
 Randomized, Open-Label, Noninferiority Study. JACC Clin Electrophysiol. 2021;7(8):1052-60.

2515.Banavalikar B, Shenthar J, Padmanabhan D, Valappil SP, Singha SI, Kottayan A, et al.252Clinical and Electrophysiological Correlates of Incessant Ivabradine-Sensitive Atrial253Tachycardia. Circ Arrhythm Electrophysiol. 2019;12(8):e007387.

6. Xu X, Guo Y, Gao W, Huang M, Liu T, Li F. Ivabradine monotherapy in pediatric patients with focal atrial tachycardia: a single-center study. Eur J Pediatr. 2023;182(5):2265-71.

2577.Janson CM, Tan RB, Iyer VR, Vogel RL, Vetter VL, Shah MJ. Ivabradine for treatment of258tachyarrhythmias in children and young adults. HeartRhythm Case Rep. 2019;5(6):333-7.

8. Michel H, Heißenhuber F, Wellmann S, Melter M, Gerling S. Ectopic Atrial Tachycardia
in a 12-Month-Old Girl Treated With Ivabradine and Beta-Blocker, a Case Report. Front
Pediatr. 2020;8:313.

9. Hackett G, Lin TK, Imundo JR. Use of ivabradine in a critically ill pediatric patient with
recalcitrant ectopic atrial tachycardia and complex congenital heart disease. HeartRhythm
Case Rep. 2022;8(6):415-9.

265 10. Cohen MI, Cohen JA, Shope C, Stollar L, Collazo L. Ivabradine as a stabilising anti-266 arrhythmic agent for multifocal atrial tachycardia. Cardiol Young. 2020;30(6):899-902.

267 11. Doctor P, Scott WA, Tindel K, Nguyen HH. Ivabradine Overdose in a Newborn:
268 Precautions of Dispensing in Infants. Cardiol Res. 2022;13(4):242-5.

Salerno JC, Kertesz NJ, Friedman RA, Fenrich AL, Jr. Clinical course of atrial ectopic
tachycardia is age-dependent: results and treatment in children < 3 or > or =3 years of age. J
Am Coll Cardiol. 2004;43(3):438-44.

Shamszad P, Cabrera AG, Kim JJ, Moffett BS, Graves DE, Heinle JS, et al. Perioperative
atrial tachycardia is associated with increased mortality in infants undergoing cardiac
surgery. J Thorac Cardiovasc Surg. 2012;144(2):396-401.

14. Kang KT, Etheridge SP, Kantoch MJ, Tisma-Dupanovic S, Bradley DJ, Balaji S, et al.
Current management of focal atrial tachycardia in children: a multicenter experience. Circ
Arrhythm Electrophysiol. 2014;7(4):664-70.

15. Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PEF. Ivabradine in Children With
Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. J Am Coll Cardiol.
2017;70(10):1262-72.

16. Ho J, Tumkaya T, Aryal S, Choi H, Claridge-Chang A. Moving beyond P values: data
analysis with estimation graphics. Nat Methods. 2019;16(7):565-6.

17. Liu CF, Cheung JW, Ip JE, Thomas G, Yang H, Sharma S, et al. Unifying Algorithm for
Mechanistic Diagnosis of Atrial Tachycardia. Circ Arrhythm Electrophysiol. 2016;9(8).

18. de Groot NM, Zeppenfeld K, Wijffels MC, Chan WK, Blom NA, Van der Wall EE, et al.
Ablation of focal atrial arrhythmia in patients with congenital heart defects after surgery:
role of circumscribed areas with heterogeneous conduction. Heart Rhythm. 2006;3(5):52635.

19. Drogalis-Kim DE, Gallotti RG, Blais BA, Perens G, Moore JP. Clinical and
electrophysiological properties of atrial tachycardia after pediatric heart transplantation.
Pacing Clin Electrophysiol. 2018;41(9):1093-100.

292 20. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable 293 coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091-9.

- 294 21. Fontenla A, Tamargo J, Salgado R, López-Gil M, Mejía E, Matía R, et al. Ivabradine for
  295 controlling heart rate in permanent atrial fibrillation: A translational clinical trial. Heart
  296 Rhythm. 2023;20(6):822-30.
- 297

298

### 299 Table 1

	Study population (n=15)
Baseline characteristics	
Age (months)	7 [1-18]
Weight (kg)	6.7 [3.9-8.5]
Gender (kg)	9/15 (60%)
Complex congenital heart disease	12/15 (80%)
Diminished systolic ventricular function	4/15 (27%)
Medication characteristic	
Therapy indication:	
First line	4/15 (27%)
Second line	6/15 (40%)
Third line	1/15 (7%)
Breakthrough	4/15 (27%)
Maximum ivabradine dose (mg/kg/dose)	0.07 [0.05-0.10]
Monotherapy	2/15 (13%)
Concurrent anti-arrhythmic medications:	
Flecainide	4/15 (27%)
Amiodarone	4/15 (27%)
Beta-blocker	4/15 (27%)
Digoxin	3/15 (20%)
Dexmedetomidine	2/15 (13%)
Outcomes	

Acute success	12/15 (80%)
Adverse events:	7/15 (33%)
Sinus bradycardia	5/15 (33%)
Functional bradycardia	2/15 (13%)

300

301